Biotechnology

Techseriesinsight > Blog > News > Biotechnology

January 19, 2026
Business Wire
Biotechnology, News

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

A leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s...

January 19, 2026
Business Wire
Biotechnology, News

ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment of adult patients with...

January 19, 2026
Business Wire
Biotechnology, News

Median Technologies Reports Landmark 2025 Performance With Major Regulatory and Commercial Milestones Ahead in 2026

Median Technologies, manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based...

January 16, 2026
Business Wire
Biotechnology, News

Prime Healthcare Expands Mission in Illinois with Franciscan Health Olympia Fields

Prime Healthcare today announced it has entered into an asset purchase agreement with Franciscan Alliance to acquire Franciscan Health Olympia Fields, further expanding Prime’s mission-driven presence in Chicagoland and...

January 16, 2026
Business Wire
Biotechnology, News

Autobahn Therapeutics Presents New Preclinical Data at ACNP Annual Meeting Supporting Novel Restorative Neuroplasticity Mechanism of Elunetirom

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the presentation of new preclinical data for elunetirom, the company’s lead...

January 13, 2026
Business Wire
Biotechnology, News

Arches Medical Rhode Island Reports Progress in Primary Care Turnaround, Expands Access Amid Statewide Capacity Shortage

As Rhode Island’s primary care system continues to face sustained strain, the state’s largest independent primary care practice made significant progress in 2025 strengthening operations and expanding access to...

January 12, 2026
Business Wire
Biotechnology, News

NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

A leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company’s Chief...

January 8, 2026
Business Wire
Biotechnology, News

During J. P. Morgan Healthcare Week, Biotech Showcase™ Provides Private and Micro- to Mid-Cap Public Company Executives One-Stop Access to Investors, Pharma Partners and Media

More than 3,000 leaders within biotechnology are registered to attend Biotech Showcase 2026 during J.P. Morgan Healthcare Week for unmatched opportunity to forge critical investment and partnering relationships as well as...

January 7, 2026
Business Wire
Biotechnology, News

Corsera Health Announces $80 Million Series A Financing and Reaches Key Clinical Milestone

Corsera Health, Inc., a clinical-stage company leading the future of cardiovascular health through prediction and prevention, announced it has raised $80 million in a Series A financing. Forbion and...

January 7, 2026
Business Wire
Biotechnology, News

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial...